The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://tiannankrm828003.buscawiki.com/1992793/retatrutide_vs_tirzepatide_a_comparative_analysis